Targeting drug-tolerant persister cells to overcome resistance in HER2-positive gastric cancer
- 21 November 2025
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 217, 105036
Abstract
No abstract availableKeywords
Funding Information
- Shandong Province Natural Science Foundation (ZR2022QH322)
- National Key Research and Development Program of China (2023YFC2506700)
- National Natural Science Foundation of China (82472366)
This publication has 147 references indexed in Scilit:
- Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancerCancer Communications, 2023
- Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal CancerJAMA Oncology, 2022
- Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501BCancer Chemotherapy and Pharmacology, 2019
- Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trialCancer Chemotherapy and Pharmacology, 2019
- Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinibMolecular Carcinogenesis, 2018
- Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancerJournal of Gastroenterology, 2018
- HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical researchInternational Journal of Cancer, 2016
- Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancerGastric Cancer, 2014
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerGastric Cancer, 2014
- HER2-positive gastric cancerGastric Cancer, 2013